ARTICLE | Clinical News
ValiRx preclinical data
June 18, 2012 7:00 AM UTC
In a mouse model of prostate cancer, VAL201 significantly inhibited tumor proliferation and reduced the spread of secondary tumors by up to 50%. ValiRx plans to start a Phase I trial of VAL201 in Euro...